Holen Sie sich die Stockscreener-App
6.15
8.48%
-0.57
Handel nachbörslich:
6.19
0.04
+0.65%
Agenus Inc Aktie (AGEN) Neueste Nachrichten
What analysts say about Agenus Inc. stockConsistently profitable trades - Jammu Links News
Is Agenus Inc. a good long term investmentMarket-beating performance - Jammu Links News
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Zydus Lifesciences receives final approval from USFDA for Celecoxib Capsules - MarketScreener
AGEN Stock Outpaces Medical Sector Peers This Year - AInvest
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains? - Yahoo Finance
Public Companies Hold Majority of MiNK Therapeutics Stock After 815% Gain - AInvest
Agenus Responds to New Regulatory Environment at FDA - Oncodaily
Agenus Inc. shares surge 19.54% intraday after positive clinical data and strategic partnership. - AInvest
Zacks.com featured highlights Yext, Agenus and NCR Voyix - The Globe and Mail
Agenus stock maintains Buy rating at H.C. Wainwright after positive bot/bal data - Investing.com Canada
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts - Baystreet.ca
Agenus Inc. shares fall 1.35% in after-hours trading after FDA questions efficacy data for BOT/BAL combination. - AInvest
Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - Oncodaily
Agenus' BOT/BAL in MSS CRC: A Breakthrough with Accelerated Approval on the Horizon? - AInvest
Agenus reports 42% two-year survival in colorectal cancer trial - Investing.com
Agenus' BOT/BAL Combo Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward FDA Registration with Phase 3 Trial Design Alignment. - AInvest
42% Survival Rate: Agenus Cancer Drug Shows Breakthrough in Resistant Colorectal Cancer | AGEN Stock News - Stock Titan
Agenus Inc. shares surge 8.17% intraday after HC Wainwright & Co. analyst upgrades rating to strong buy. - AInvest
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Agenus Requests to Dismiss Class Action Filed by Investors - TradingView
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell Small Cap Completeness Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2000 Growth Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2500 Index - MarketScreener
Agenus Holds Annual Stockholders Meeting on June 17 - TipRanks
# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener
Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus
Agenus, Noetik Enter Research Collaboration - Nasdaq
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus
AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan
10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.
Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus Announces Virtual Annual Shareholders Meeting - New Castle News
How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan
Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN
Agenus' 2025 Annual Meeting Highlights Pipeline Breakthroughs and Governance Gains, Bolstering Oncology Innovation Play - AInvest
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts - Defense World
Research Analysts Issue Forecasts for Agenus FY2027 Earnings - Defense World
HC Wainwright Forecasts Agenus’ Q3 Earnings (NASDAQ:AGEN) - Defense World
Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues
Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International
Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World
Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):